This report aims to provide detailed insights into the Oligonucleotide Synthesis Market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.
Revenue Growth Analysis:
[246 Pages Report] The global oligonucleotide synthesis market is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6%.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Key Factors Driving Market Growth:
The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine.
Increasing government investments for synthetic biology and genome projects
In recent years, governments in various countries have made significant investments in projects related to the field of synthetic biology and genomics. These government investments have played a major role in the development of new technologies. Oligos form an integral part of these technologies, and increasing funding & developments in these fields will drive market growth for oligonucleotides. For instance;
1. In January 2020, the Department of Biotechnology (DBT) initiated the “Genome India Project” (GIP). The project aims to collect 10,000 genetic samples from citizens across India to build a reference genome. Some focus areas of this project are precision health, rare genetic disorders, mutation spectrum of genetic & complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research.
2. In February 2021, the Centre for Process Innovation (CPI) launched a project in the Medicines Manufacturing Innovation Centre in the UK. This project aims to revolutionize the manufacturing of oligonucleotides through a collaboration with AstraZeneca, Exactmer, Novartis, and the UK Research & Innovation. Inclisiran, a small interfering RNA used in the treatment of atherosclerotic cardiovascular disease (ASCVD), would be the first medicine produced at a commercial scale as a result of this collaboration.
3. In August 2019, the Li Ka Shing Foundation (Hongkong) donated USD 63 million to launch a major institute for synthetic biology research at the Hong Kong University of Science and Technology (HKUST). The new institute will conduct research in synthetic biology, combining the materials and processes of biological systems & engineering.
4. In September 2019, a whole-genome sequencing project of USD 224 million was created, forming a partnership of pharmaceutical firms and health experts, which will examine and sequence the genetic code of 500,000 volunteers at the UK Biobank, based in Stockport, UK. The project aims to improve health through genetic research and improve the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses, including cancer, heart diseases, diabetes, arthritis, and dementia.
5. In February 2019, the Minister of Science and Sport (Canada) announced the funding of USD 22.7 million in addition to funding of USD 33.4 million by provincial governments to support 36 research projects through Genome Canada. The projects include various sectors such as health, agriculture, natural resources, and the environment.
6. In January 2019, the National Institutes of Health (NIH) awarded 24 grants to researchers across the US and Canada through the Somatic Cell Genome Editing (SCGE) Program. This group of awards from the SCGE Program totals approximately USD 89 million over four years.
These ongoing government-sponsored projects will lead to improvements in genomic technologies, specifically in DNA sequencing, DNA amplification, NGS, and gene expression. Also, oligos form an integral part of these technologies; therefore, an increase in government-funded projects will positively impact the overall growth of the oligonucleotide synthesis market.
Hospitals accounted for the largest share of the Oligonucleotide Synthesis Market, by end user, in 2020
Based on end user, the DNA Synthesis Industry is segmented into academic research institutes, diagnostic laboratories, pharmaceutical & biotechnology companies, and hospitals. Hospitals accounted for the largest share of the DNA Synthesis Market in 2020. Growth in this end-user segment is largely driven by the significant number of inpatient and outpatient visits in hospitals and the high requirement of oligonucleotide drugs to cater to the demand from the vast patient pool suffering from diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and hepatic veno-occlusive disease.
North America was the largest regional market for oligonucleotide synthesis in 2020
In 2020, North America accounted for the largest market share. The large share of this region can be attributed to the increasing R&D in life sciences, rising focus on improving the safety & quality of healthcare, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics. The presence of many global players in this region is another key factor contributing to the large share of this market segment.
Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350
Key Market Players:
The oligonucleotide synthesis market is dominated by a few globally established players such as Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).
Oligonucleotide Synthesis Market Growth Strategies, Size and Latest Trends
According MarketsandMarkets Research – The Rat Model Market is expected to reach USD 588.9 million, at a CAGR of 8.7%.Application of Rat Model in Detailed:Rat model applications in various therapeutic indications such as toxicology, oncology, diabetes, neurology, immunology and infectious diseases, and others (rare disease, cardiovascular, metabolic disease, hematopoiesis, and regenerative medicines) coupled with the increase in R activities carried out by pharmaceutical and biotechnology companies drive the growth of rat model marketDIABETES:Rats are considered to be excellent experimental models for understanding the complex genetic basis of diseases such as diabetes.
However, it is quite difficult to carry out research studies in human beings, owing to problems such as genetic heterogeneity and lack of controlled lifestyles.
Rat models act as suitable models to study specific genetic mutations and to understand the function of genes on a homogeneous genetic background.Browse 132 market data tables and 47 figures spread through 253 pages and in-depth TOC | Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76036494Market Segmentation in Depth:On the basis of type, the rat model market is segmented into outbred rats, inbred rats, knockout/genetically engineered rats, hybrid/congenic rats, conditioned/surgically modified rats, and immunodeficient rats model.
Knockout/genetically engineered rats segment is expected to grow at the highest CAGR during the forecast period.
The high growth rate of knockout/genetically engineered rats segment can be attributed to the use of this type of rat model to carry out researches on disease such as oncology, obesity, heart disease, diabetes, arthritis, drug abuse, anxiety, aging, and Parkinson’s.On the basis of services, the rat model market is segmented into breeding, cryopreservation, quarantine, rederivation, model in-licensing, genetic testing, and others such as surgical services, line rescue services, and in vivo pharmacology services.
The cryopreservation segment is estimated grow at the highest CAGR during the forecast period, as this segment help in obtaining the genetic material of rats even after the reproductive lifespan of these rats is over.
Many long-lasting new firms have owners who undertake systematic market research to understand their target market better, uncover customer concerns, and discover credible rivals.Visit Us:- https://www.convrtx.com/blog/advantages-of-doing-market-research-for-a-start-up/#marketresearch
Rising geriatric population, growing prevalence of chronic diseases, increasing number of diagnostic centers, and increasing physician awareness & demand for histopathology are expected to fuel the growth of this market in the coming years.
However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine offer significant growth opportunities in the immunohistochemistry market.The immunohistochemistry market is projected to reach USD 2.12 billion by 2021, at a CAGR of 7.3% during the forecast period.
Antibodies segment to dominate the global immunohistochemistry marketBased on products, the market is segmented into antibodies, reagents, kits, and equipment.
In 2015, the antibodies segment accounted for the largest share of the global immunohistochemistry market.
The rising adoption of high-throughput assays, such as array comparative genomic hybridization, cDNA microarray, next-generation sequencing techniques, and histological tests, have led to the rapid discovery of thousands of potential antibodies.Diagnostics segment accounted for largest share of immunohistochemistry marketImmunohistochemistry market is categorized into two application segments, namely, diagnostics and drug testing.
The global market for diagnostic applications is further segmented into infectious diseases, cancer, cardiovascular diseases, diabetes, autoimmune diseases, and nephrological diseases.
Hypersomnia API Manufacturers and Marketed Products – Market Research ReportThis report provides comprehensive insights about marketed and Phase III products for Hypersomnia.
The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for HypersomniaCoverage of API manufacturers for Hypersomnia marketed products spanning across United States, Europe, China, and India.
The manufacturers’ details include manufacturers’ name along with their location.
Emerging Phase III products for HypersomniaThis report provides a comprehensive understanding of the emerging Phase III therapies for Hypersomnia which can turn out to be future prospective competitors for the marketed products.
It will also put light on the current market trends.
According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.Download PDF Brochure :https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724The factors driving market growth include growing incidence of chronic diseases, rising focus on preventive healthcare, technological advancements, growing need to control healthcare costs, significant increase in venture capital investments, and the benefits of digital therapeutics.
However, factors such as lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, and resistance from traditional healthcare providers may restrain the digital therapeutics market growth.Browse and in-depth TOC on "Digital Therapeutics Market"148 - Tables186 - Pages36 - FiguresOrder a copy of “Digital Therapeutics Market Size & Share | Industry Analysis” research study at:https://www.marketsandmarkets.com/PressReleases/digital-therapeutics.aspThe digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.
Each segment has different market players and market leaders.
For instance, the prediabetes market was led by Omada in 2015.
Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease.
Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program.
The method of identifying the genetic code of an organism into the DNA sequence is known as DNA sequencing.
It refers to any approach or procedure used to determine how the four bases in DNA are arranged in a DNA sequence.
Chemical ionisation and connection of DNA sequencing equipment and services to an alkaline base are used in other approaches.The advantages of DNA sequencing equipment and services over alternative technologies are numerous.
For starters, precise measurements can be made without changing the DNA structure.
It also identifies regions of DNA sequence variation.
This allows DNA sequencing equipment and services to be used in a variety of fields of DNA biology, including inherited disorders and ageing.
The Mucus Clearance Devices Market is assessed to have solid development later on.
The locale likewise has the most noteworthy understudy populace, and with propelling advancements, there is a developing interest for eLearning and distance training.
This drives the healthcare business sector to meet broadened instructive prerequisites across different nations in the APAC district, like Australia and New Zealand (ANZ), Japan, China, Singapore, and India.Attributable to the flare-up of COVID-19, different nations follow severe lockdowns, closures, and portability limitations to stay away from the spread of the infection.
Merchants have encountered appeal for Smart Learning arrangements during 2020.
Conclusion of lines, rigid lockdowns, and inventory network issues go about as limiting elements for the on location arrangement of Smart Learning arrangements.
The commercialization of Mucus Clearance Devices Market is relied upon to drive market development for an enormous scope.
1 March 2019, The global Liquid Biopsy Market is projected to witness substantial growth over the forecast period (from 2017 to 2025) owing to advancement in liquid biopsy tests and extensive R by major companies.
Moreover, highly invasive nature and frequent complications associated with tissue biopsy and advancements in Next-Generation Sequencing (NGS) is anticipated to fuel demand for liquid biopsy in coming years.Liquid biopsies make use of bio fluid samples, such as blood, urine sample, tissue fluids, and saliva.
The technology is widely used in molecular health monitoring, therapy selection for Metastatic Breast Cancer (MBS), and other related cancers.
MBS is likely to emerge as a leading application over the forecast period as a result of growing cases of metastatic cancer across the world.
PCR-based sequencing is used for analysis of mutations in disease-specific genes, whereas NGS testing is used for simultaneous analysis of multiple diseases.
Rising awareness about benefits of multiple-gene analysis and NGS is projected to have a positive impact on the market growth over the next few years.The market can be segmented on the basis of geography as North America, Latin America, Asia Pacific, Europe, and MEA.
According MarketsandMarkets Research – The Rat Model Market is expected to reach USD 588.9 million, at a CAGR of 8.7%.Application of Rat Model in Detailed:Rat model applications in various therapeutic indications such as toxicology, oncology, diabetes, neurology, immunology and infectious diseases, and others (rare disease, cardiovascular, metabolic disease, hematopoiesis, and regenerative medicines) coupled with the increase in R activities carried out by pharmaceutical and biotechnology companies drive the growth of rat model marketDIABETES:Rats are considered to be excellent experimental models for understanding the complex genetic basis of diseases such as diabetes.
However, it is quite difficult to carry out research studies in human beings, owing to problems such as genetic heterogeneity and lack of controlled lifestyles.
Rat models act as suitable models to study specific genetic mutations and to understand the function of genes on a homogeneous genetic background.Browse 132 market data tables and 47 figures spread through 253 pages and in-depth TOC | Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76036494Market Segmentation in Depth:On the basis of type, the rat model market is segmented into outbred rats, inbred rats, knockout/genetically engineered rats, hybrid/congenic rats, conditioned/surgically modified rats, and immunodeficient rats model.
Knockout/genetically engineered rats segment is expected to grow at the highest CAGR during the forecast period.
The high growth rate of knockout/genetically engineered rats segment can be attributed to the use of this type of rat model to carry out researches on disease such as oncology, obesity, heart disease, diabetes, arthritis, drug abuse, anxiety, aging, and Parkinson’s.On the basis of services, the rat model market is segmented into breeding, cryopreservation, quarantine, rederivation, model in-licensing, genetic testing, and others such as surgical services, line rescue services, and in vivo pharmacology services.
The cryopreservation segment is estimated grow at the highest CAGR during the forecast period, as this segment help in obtaining the genetic material of rats even after the reproductive lifespan of these rats is over.
The method of identifying the genetic code of an organism into the DNA sequence is known as DNA sequencing.
It refers to any approach or procedure used to determine how the four bases in DNA are arranged in a DNA sequence.
Chemical ionisation and connection of DNA sequencing equipment and services to an alkaline base are used in other approaches.The advantages of DNA sequencing equipment and services over alternative technologies are numerous.
For starters, precise measurements can be made without changing the DNA structure.
It also identifies regions of DNA sequence variation.
This allows DNA sequencing equipment and services to be used in a variety of fields of DNA biology, including inherited disorders and ageing.
Many long-lasting new firms have owners who undertake systematic market research to understand their target market better, uncover customer concerns, and discover credible rivals.Visit Us:- https://www.convrtx.com/blog/advantages-of-doing-market-research-for-a-start-up/#marketresearch
Rising geriatric population, growing prevalence of chronic diseases, increasing number of diagnostic centers, and increasing physician awareness & demand for histopathology are expected to fuel the growth of this market in the coming years.
However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine offer significant growth opportunities in the immunohistochemistry market.The immunohistochemistry market is projected to reach USD 2.12 billion by 2021, at a CAGR of 7.3% during the forecast period.
Antibodies segment to dominate the global immunohistochemistry marketBased on products, the market is segmented into antibodies, reagents, kits, and equipment.
In 2015, the antibodies segment accounted for the largest share of the global immunohistochemistry market.
The rising adoption of high-throughput assays, such as array comparative genomic hybridization, cDNA microarray, next-generation sequencing techniques, and histological tests, have led to the rapid discovery of thousands of potential antibodies.Diagnostics segment accounted for largest share of immunohistochemistry marketImmunohistochemistry market is categorized into two application segments, namely, diagnostics and drug testing.
The global market for diagnostic applications is further segmented into infectious diseases, cancer, cardiovascular diseases, diabetes, autoimmune diseases, and nephrological diseases.
The Mucus Clearance Devices Market is assessed to have solid development later on.
The locale likewise has the most noteworthy understudy populace, and with propelling advancements, there is a developing interest for eLearning and distance training.
This drives the healthcare business sector to meet broadened instructive prerequisites across different nations in the APAC district, like Australia and New Zealand (ANZ), Japan, China, Singapore, and India.Attributable to the flare-up of COVID-19, different nations follow severe lockdowns, closures, and portability limitations to stay away from the spread of the infection.
Merchants have encountered appeal for Smart Learning arrangements during 2020.
Conclusion of lines, rigid lockdowns, and inventory network issues go about as limiting elements for the on location arrangement of Smart Learning arrangements.
The commercialization of Mucus Clearance Devices Market is relied upon to drive market development for an enormous scope.
Hypersomnia API Manufacturers and Marketed Products – Market Research ReportThis report provides comprehensive insights about marketed and Phase III products for Hypersomnia.
The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for HypersomniaCoverage of API manufacturers for Hypersomnia marketed products spanning across United States, Europe, China, and India.
The manufacturers’ details include manufacturers’ name along with their location.
Emerging Phase III products for HypersomniaThis report provides a comprehensive understanding of the emerging Phase III therapies for Hypersomnia which can turn out to be future prospective competitors for the marketed products.
It will also put light on the current market trends.
1 March 2019, The global Liquid Biopsy Market is projected to witness substantial growth over the forecast period (from 2017 to 2025) owing to advancement in liquid biopsy tests and extensive R by major companies.
Moreover, highly invasive nature and frequent complications associated with tissue biopsy and advancements in Next-Generation Sequencing (NGS) is anticipated to fuel demand for liquid biopsy in coming years.Liquid biopsies make use of bio fluid samples, such as blood, urine sample, tissue fluids, and saliva.
The technology is widely used in molecular health monitoring, therapy selection for Metastatic Breast Cancer (MBS), and other related cancers.
MBS is likely to emerge as a leading application over the forecast period as a result of growing cases of metastatic cancer across the world.
PCR-based sequencing is used for analysis of mutations in disease-specific genes, whereas NGS testing is used for simultaneous analysis of multiple diseases.
Rising awareness about benefits of multiple-gene analysis and NGS is projected to have a positive impact on the market growth over the next few years.The market can be segmented on the basis of geography as North America, Latin America, Asia Pacific, Europe, and MEA.
According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.Download PDF Brochure :https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724The factors driving market growth include growing incidence of chronic diseases, rising focus on preventive healthcare, technological advancements, growing need to control healthcare costs, significant increase in venture capital investments, and the benefits of digital therapeutics.
However, factors such as lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, and resistance from traditional healthcare providers may restrain the digital therapeutics market growth.Browse and in-depth TOC on "Digital Therapeutics Market"148 - Tables186 - Pages36 - FiguresOrder a copy of “Digital Therapeutics Market Size & Share | Industry Analysis” research study at:https://www.marketsandmarkets.com/PressReleases/digital-therapeutics.aspThe digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.
Each segment has different market players and market leaders.
For instance, the prediabetes market was led by Omada in 2015.
Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease.
Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program.